Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Would New SARS-CoV-2 Variants Change the War Against COVID-19?

Elrashdy M. Redwan
* ,
Fatma Elrashdy
ORCID logo ,
Alaa A. A. Aljabali
ORCID logo ,
Wagner Baetas-da-Cruz
,
Debmalya Barh
ORCID logo ,
Adam M. Brufsky
ORCID logo ,
Sk. Sarif Hassan
ORCID logo ,
Kenneth Lundstrom
,
Ángel Serrano-Aroca
ORCID logo ,
Kazuo Takayama
ORCID logo ,
Murtaza M. Tambuwala
ORCID logo ,
Bruce D. Uhal
ORCID logo ,
Vladimir N Uversky
* ORCID logo
Version 1 : Received: 11 March 2022 / Approved: 14 March 2022 / Online: 14 March 2022 (11:19:04 CET)

A peer-reviewed article of this Preprint also exists.

Redwan, E.M.; Elrashdy, F.; Aljabali, A.A.A.; Baetas-da-Cruz, W.; Barh, D.; Brufsky, A.M.; Hassan, S.S.; Lundstrom, K.; Serrano-Aroca, Á.; Takayama, K.; Tambuwala, M.M.; Uhal, B.D.; Uversky, V.N. Would New SARS-CoV-2 Variants Change the War against COVID-19? Epidemiologia 2022, 3, 229-237. Redwan, E.M.; Elrashdy, F.; Aljabali, A.A.A.; Baetas-da-Cruz, W.; Barh, D.; Brufsky, A.M.; Hassan, S.S.; Lundstrom, K.; Serrano-Aroca, Á.; Takayama, K.; Tambuwala, M.M.; Uhal, B.D.; Uversky, V.N. Would New SARS-CoV-2 Variants Change the War against COVID-19? Epidemiologia 2022, 3, 229-237.

Abstract

The scientific, private and industrial sectors use a wide variety of technological platforms available to achieve protection against SARS-CoV-2, including vaccines. However, the virus evolves continually into new highly virulent variants, which might overcome the protection provided by vaccines and may re-expose the population to infections. Mass vaccinations should be continued in combination with more or less obligation mandatory non-pharmaceutical interventions. Therefore, the key questions to be answered are: (i) How to identify the primary and secondary infections of SARS-CoV-2? (ii) Why are neutralizing antibodies not long-lasting in both the cases of natural infections and post-vaccinations? (iii) Which are the factors responsible for this decay in neutralizing antibodies? (iv) What strategy could be adapted to develop long-term herd immunity? (v) Is the Spike the only vaccine candidate or a vaccine cocktail is better?

Keywords

SARS-CoV-2; COVID-19; variant; sublineage; transmission; immunity; infection; vaccination; non-pharmaceutical interventions

Subject

Medicine and Pharmacology, Pulmonary and Respiratory Medicine

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.